Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1812 DDI Study with CYP Probes
NCT03716427Phase 1Completed
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zervimesine in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc. Primary endpoint: Area under the plasma-concentration time curve at Day 6. Started Nov 2016; status: completed.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03716427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03716427.